ketoprofen structure
Find information on thousands of medical conditions and prescription drugs.

Oruvail

Ketoprofen, (RS)2-(3-benzoylphenyl)-propionic acid (chemical formula C16H14O3) is one of the propionic acid class of non-steroidal anti-inflammatory drug (NSAID) with analgesic and anti-pyretic effects. It acts by inhibiting the body's production of prostaglandin.

Ketoprofen is available OTC in the United States in the form of 12.5mg coated tablets (Orudis KT®). It is also available by prescription as 25, 50, 75, 100, 150, and 200mg capsules.

Brand names in the US are Orudis and Oruvail.

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
Methoxsalen
OCL
Octabenzone
Octanoic acid
Octopamine
Octreotide
Ofloxacin
Ofloxacin
Olanzapine
Omeprazole
Oncovin
Ondansetron
Opium
Oratane
Oretic
Orinase
Orlistat
Ornidazole
Ornithine
Orotic acid
Orphenadrine
Ortho Evra
Oruvail
Ovcon
Ovral
Ovrette
Oxaliplatin
Oxamniquine
Oxandrin
Oxandrolone
Oxaprozin
Oxazepam
Oxcarbazepine
Oxetine
Oxibendazole
Oxiracetam
Oxprenolol
Oxybenzone
Oxybuprocaine
Oxycodone
Oxycodone
Oxymetazoline
Oxymetholone
Oxymorphone
Oxytetracycline
Oxytocin
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


FDA Approves ANDA for Oruvail
From Business Wire, 3/30/99

FORT LAUDERDALE, Fla. and CORONA, Calif.--(BUSINESS WIRE)--March 30, 1999--Andrx Corporation (Nasdaq:ADRX) and Watson Pharmaceuticals, Inc. (NYSE:WPI) today announced that the United States Food and Drug Administration (FDA) has approved an Abbreviated New Drug Application (ANDA) submitted by their joint venture, ANCIRC Pharmaceuticals for bioequivalent versions of Oruvail(R).

Marketed by the Wyeth Ayerst division of American Home Products, Inc., Oruvail(R) (Ketoprofen Extended-release Capsules) is used in the treatment of arthritis. This product was developed by Andrx and will also be manufactured and marketed by Andrx on behalf of ANCIRC.

Andrx is engaged in the formulation and commercialization of oral

controlled-release pharmaceuticals utilizing its proprietary drug delivery technologies. In its ANDA program, Andrx is developing generic versions of selected high sales volume controlled-release brand name pharmaceuticals. In its NDA program, Andrx is developing its own brand name formulations of certain existing drugs that it believes may be improved by the application of the Andrx' drug delivery technologies. Andrx also distributes pharmaceutical products manufactured by third parties and is developing Internet based software applications to improve the provision of healthcare.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the development, manufacture and sale of proprietary and off-patent pharmaceutical products. Watson pursues a strategy of generating revenue through established proprietary and off-patent businesses, capitalizing on its proven ability to support the development of these drugs in the therapeutic areas of primary care, women's health, dermatology and neurology/psychiatry.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contacts: Elliot F. Hahn, Ph.D., President of Andrx Corporation, 4001 S.W. 47th Avenue, Fort Lauderdale, Florida 33314, 954-584-0300. This release and additional information about Andrx Corporation are also available on the Internet at: http://www.Andrx.com. Sara Swee, Corporate Communications of Watson Pharmaceuticals, Inc., 909-270-1400. This and past press releases of Watson Pharmaceuticals, Inc. are available at Watson's web site at www.watsonpharm.com. In addition, press releases are available through PR Newswire's Company News On-Call fax service at 800-758-5804, extension 112856, and at www.prnewswire,com.

COPYRIGHT 1999 Business Wire
COPYRIGHT 2000 Gale Group

Return to Oruvail
Home Contact Resources Exchange Links ebay